TTU_2005

500 posts

TTU_2005

TTU_2005

@olearyttu

Houston, TX Katılım Ağustos 2017
288 Takip Edilen87 Takipçiler
TTU_2005
TTU_2005@olearyttu·
@unusual_whales That is not my experience using them to help with doagnose in clinic. Its actually very good imo.
English
0
0
0
30
unusual_whales
unusual_whales@unusual_whales·
AI chatbots misdiagnose in over 80% of early medical cases, per FT.
English
325
686
6.1K
536.4K
Polymarket
Polymarket@Polymarket·
JUST IN: New analysis reveals Brits thought the UK ranked 7th against US states in income per person — it actually ranked 51st.
English
1.1K
2.8K
37.9K
13.2M
TTU_2005
TTU_2005@olearyttu·
@DrSiyabMD Is this a joke?? Zofran is given out in the hospital like candy. Noone is checking QTc
English
0
0
11
180
TTU_2005
TTU_2005@olearyttu·
@hjluks At first i thought this was a joke about the pannus + knee pain.
English
0
0
2
1.2K
Howard Luks MD
Howard Luks MD@hjluks·
This should be a never event. Second opinion for knee replacement. Granted. Complaint was knee pain. Not hip pain. Only knee pain 🤦‍♂️ Rotate the femur folks.
Howard Luks MD tweet mediaHoward Luks MD tweet media
English
35
7
174
91.6K
Conrad Fischer
Conrad Fischer@SeeFisch·
If Syria is our friend, and I certainly consider myself a friend of Syrians, then why do we block their visas to come to America to be doctors? Get the BEST BRAINS for free!
Chief of the Defence Staff@UKCDS_MOD

Yesterday I was able to meet with President Al Sharaa of Syria. We discussed opportunities for closer collaboration to work towards longer-term regional stability through counter terrorism and on avoiding escalation during the ongoing conflict in the Middle East.

English
30
23
356
42.2K
TTU_2005
TTU_2005@olearyttu·
@SMB_Attorney Only thing I can think of is that they were trying to get hype to increase their valuation then a sell off to private equity.
English
0
0
2
489
SMB Attorney
SMB Attorney@SMB_Attorney·
Why on God's green earth would you allow the New York Times to do a profile on you bragging about your fat margins if you have nothing proprietary, no moat... zero way of stopping copy cats? Something's not adding up!
Jon Oringer@jonoringer

The NYT just profiled a $1.8B revenue company with 2 employees. Medvi is a telehealth GLP-1 provider built by Matthew Gallagher, 41, from his house in LA. He launched in September 2024 with $20,000. Here are the numbers: Month 1: 300 customers Month 2: 1,300 customers 2025 full year: $401M revenue, 250,000 customers 2026 run rate: $1.8B Net margin: 16.2% ($65M profit) Total employees: 2 (him and his brother) Outside funding: $0 How it works: Medvi is a front end. Two platforms — CareValidate and OpenLoop Health — handle doctors, prescriptions, pharmacies, shipping, and compliance. Gallagher handles brand, website, ads, checkout, and customer service. All built with AI. His stack: ChatGPT, Claude, and Grok for code. Midjourney and Runway for ad creative. ElevenLabs for voice. Custom AI agents to connect systems. AI chatbot for customer service (which initially hallucinated fake prices he had to honor). For comparison: Hims & Hers did $2.4B revenue last year with 2,442 employees and 5.5% net margins. Gallagher is running 3x the margin with a fraction of a percent of the headcount. Back into the unit economics: ~$336M in total costs, probably $160-200M to the telehealth platforms, leaving $130-170M mostly in marketing. Against 250,000 customers, that's a $500-700 CAC. High, but it works because his overhead is virtually zero and LTV at ~$200/month holds up. He's expanding fast. Men's health launched in February — 50K customers in month one. Meal delivery went live last month. Women's health, hair growth, supplements, and skincare are next. The vulnerability: zero moat. No proprietary tech, no doctor network, no pharmacy infrastructure. CareValidate or OpenLoop could raise fees or launch competing brands. Anyone could replicate this model in weeks. Right now, the margins are enormous for anyone who moves fast enough. The question is how long that window stays open. nytimes.com/2026/04/02/tec…

English
59
24
1.3K
207.2K
TTU_2005
TTU_2005@olearyttu·
@rorynotsorry When you switch from semaglutide to tirzepatide you are supposed to start at the lowest dose of tirz because of the addition of GIP analog but i typically will start patients at 5mg. Still get calls from pharmacist though warning against it.
English
0
0
0
74
Rory Not Sorry
Rory Not Sorry@rorynotsorry·
Hey, MD’s. One of the questions I see a lot is how to switch from one GLP1 to another? Say from prescribed Ozempic to prescribed Tirzepatide. My thought has always been to just switch over without any delay and to just titrate up normally. As the levels decrease in your system from one they will slowly build up in the other. I also think that you could probably tie straight up a tiny bit faster than the standard four weeks. But I’m curious as to what the experts say.
English
9
0
10
5K
TTU_2005
TTU_2005@olearyttu·
@bschermd The AHA is a joke. That doesnt mean the USDA is right about everything but all of these professional medical organizations agendas are driven by their contributors.
English
1
0
11
1.9K
Bret Scher, MD
Bret Scher, MD@bschermd·
No wonder you're confused about what to eat. The two biggest dietary guideline organizations in the US just released opposing recommendations (American Heart Association vs. USDA). Here's where the two guidelines agree, disagree, and what the science says. 🧵
Bret Scher, MD tweet media
English
20
65
336
66.9K
Steve Baker
Steve Baker@SteveBakerUSA·
We retracted NOTHING, and nothing that @HanneReports and I have published has been “debunked.” Oh, sure … MSM outlets, @FBI “sources,” and members of the Former Agents Group (F.A.G.s) have all said, “Nuh-uh,” but that isn’t “debunking.” That’s not doing the work themselves, and showing different results. No one has yet done that. They are still only parroting the intel community’s narrative — told through “sources” who also haven’t done the work — delivering the message they’ve been assigned to spread. The muzzle has been discarded. There is no longer a paycheck-imposed gag order. Joe and I are now free to tell all. Announcements coming soon.
Steve Baker tweet media
English
230
1.5K
6.2K
517.8K
TTU_2005
TTU_2005@olearyttu·
@grok @AlexFinn @grok what is the level of performance on the 31B Dense model? Any comparisons to old frontier models?
English
1
0
0
46
Grok
Grok@grok·
Gemma 4 VRAM needs (approx, Q4/Q5 quantized, 128K-256K context): - E2B (2.3B eff.): ~3GB – phone/laptop friendly - E4B (4.5B eff.): ~5-7GB - 26B A4B MoE (3.8B active): ~6-10GB (runs like a ~4B model) - 31B Dense: ~15-22GB (consumer GPU sweet spot) LM Studio/Ollama auto-detects best fit for your hardware. Edge models shine on-device; bigger ones need a decent GPU or Mac unified memory. Full specs in the model card.
English
1
0
0
126
Alex Finn
Alex Finn@AlexFinn·
Do you even understand what this means? An open source model just released that is: • Outperforms models 20x its size • Can run on a base model Mac Mini • Is AMERICAN 🇺🇸 If you have a base model Mac Mini you can have unlimited super intelligence on your desk. For free. Sonnet 4.5 was released 5 months ago In 5 months that level of intelligence went from frontier to free on your desk And not only that, can run on any basically any computer out there If you have even a remotely modern computer, do the following immediately: 1. Download LM Studio 2. Go to your OpenClaw and ask which of these new Gemma 4 models is best for your hardware 3. Have it walk you through downloading and loading it 4. Build apps with it knowing you are using your own personal, private super intelligence on your desk The people denying this is the future are so beyond lost.
Google DeepMind@GoogleDeepMind

Meet Gemma 4: our new family of open models you can run on your own hardware. Built for advanced reasoning and agentic workflows, we’re releasing them under an Apache 2.0 license. Here’s what’s new 🧵

English
282
560
7.1K
1.3M
TTU_2005
TTU_2005@olearyttu·
@DrJesseMorse @grok where does the new plasma come from that goes back in to the patient in plasma exchange?
English
1
0
0
405
Jesse Morse, M.D.
Jesse Morse, M.D.@DrJesseMorse·
Therapeutic Plasma Exchange (TPE) is now live at our Miami office! You may have seen Joe Rogan post about it last weekend. That’s my partner Dr. Goddard, and 20% of all of his plasma (blood) with toxins in it. Think microplastics, heavy metals, PFAS, and other toxins in his blood. Light yellow is a normal color, but darker yellow and sometimes green means there’s lots of toxins that were removed from the body. Wrote a full article here discussing it here: open.substack.com/pub/drjessemor…
Jesse Morse, M.D. tweet mediaJesse Morse, M.D. tweet media
English
26
14
203
43.2K
𝙳𝚊𝚟𝚒𝚍 𝙲𝚊𝚗𝚎𝚜
If a patient with low testosterone on testosterone replacement has an elevated PSA and you begin your workup, say, with an MRI, why tell the patient to stop the T replacement? Think about this: If a patient with normal testosterone has an elevated PSA, we don't castrate them while we proceed with a workup. Let people have a quality of life.
English
7
4
62
7.2K
TTU_2005
TTU_2005@olearyttu·
@grok @tex_todd @MichaelAlbertMD @grok which pharmaceutical company funded the trials involving the new oral pcsk9 inhibitor? How much is it expected to cost per month when it comes out? Did they look at pcsk9/statin cotherapy versus high intensity statin alone?
English
1
0
0
89
Grok
Grok@grok·
In these trials (Ez-PAVE, VESALIUS-CV, CORALreef), safety profiles were similar between intensive LDL-lowering arms and controls/placebo. No significant increase in serious adverse events, muscle issues, diabetes, or other harms. Discontinuation rates matched placebo (~2-4%). NNH for major harms isn't elevated—effectively very high (>1,000 in similar PCSK9/statin trials) or not calculable due to no excess risk. Benefits outweighed harms at these LDL targets.
English
1
0
0
116
Michael Albert, MD
Michael Albert, MD@MichaelAlbertMD·
The cholesterol wars are over. LDL won. New guidelines. Four landmark trials. An oral PCSK9 inhibitor that matches injectables. And data proving we should be treating patients we currently aren't. Here's everything clinicians need to know. 🧵
English
177
441
3K
1.3M
Grok
Grok@grok·
In the Ez-PAVE trial (secondary prevention, n=3,048 ASCVD patients), nonfatal MI rates were 0.8% (intensive LDL <55 mg/dL) vs 1.7% (conventional <70 mg/dL) at 3 years. ARR=0.9%, so NNT≈111 to prevent one nonfatal MI. In VESALIUS-CV (high-risk primary prevention, n=12,257 diabetics/atherosclerosis without prior MI/stroke), evolocumab reduced MI risk by 36% (ARR=1.4%) over 4.6 years median follow-up. NNT≈71 to prevent one MI. CORALreef trials focused on LDL reduction/safety, not yet on clinical MI outcomes. NNTs depend on baseline risk and duration.
English
1
0
0
171
TTU_2005
TTU_2005@olearyttu·
@anish_koka When only ~11% of health care workers are taking the covid boosters that tells you something!
English
0
0
0
25
Anish Koka, MD
Anish Koka, MD@anish_koka·
Weird. We were reliably told by many experts that the only way to keep COVID at bay was infinity covid boosters.
Anish Koka, MD tweet media
English
8
3
34
1.5K